Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Immunic appoints Elena Ridloff to board ahead of key Phase 3 MS trial data and potential commercialization.
ACAD
$28.30
-$0.08 -0.28%

Immunic appoints Elena Ridloff to board ahead of key Phase 3 MS trial data and potential commercialization.

Company Fundamentals
10 Aug 2026
PRNewsWire
View Source
Bullish
pluang ai news

Immunic, a late-stage biotech company, has appointed Elena Ridloff, CFA, to its Board of Directors as it approaches critical milestones in its development of vidofludimus calcium for multiple sclerosis (MS). Ridloff brings over 20 years of financial and capital markets expertise in biopharma, expected to support Immunic's growth during upcoming Phase 3 ENSURE trial results and planned regulatory filings. The company anticipates top-line data from its Phase 3 trial in relapsing MS by the end of 2026 and plans to start a confirmatory Phase 3 trial in progressive MS. Ridloff's experience is seen as valuable for advancing the drug's potential and commercial strategy.

More News (ACAD)

ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.

ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.

ACADIA Pharmaceuticals reported strong Q2 2026 results, with earnings of $0.18 per share beating estimates by 200% and revenues of $307.96 million surpassing forecasts by nearly 5%. Driven by increased sales of key drugs Daybue and Nuplazid, the comp...

Company Fundamentals
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App